New pill HRS-7535 takes on diabetes in Head-to-Head trial
NCT ID NCT06589765
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study compares a new drug, HRS-7535, to an existing diabetes medication, dapagliflozin, in adults with type 2 diabetes whose blood sugar is not well controlled with metformin alone. The goal is to see if HRS-7535 works better at lowering blood sugar and body weight over 32 weeks. About 810 participants will take either HRS-7535 or dapagliflozin, without knowing which they receive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-7535
What this could lead to
If successful, HRS-7535 could offer a new oral option for better blood sugar control and weight loss in type 2 diabetes.
What could go wrong
This is an early-phase comparison; HRS-7535 may not prove superior to dapagliflozin, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China